Healio20h
Patients with chronic spontaneous urticaria see well-controlled disease with briquilimab
Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...
Blueprint Medicines price target lowered to $124 from $135 at Wedbush
Wedbush lowered the firm’s price target on Blueprint Medicines (BPMC) to $124 from $135 and keeps an Outperform rating on the shares. The firm ...
Daily6d
Study Reveals Increased Risk of Skin Conditions like Urticaria, Vitiligo, and Herpes Zoster Following COVID-19 Infection
A recent population-based study from South Korea highlights the long-term dermatological complications linked to COVID-19 ...
Promising Outlook for Allakos’s AK006 in Treating Chronic Spontaneous Urticaria Justifies Buy Rating
Analyst Silvan Tuerkcan of JMP Securities reiterated a Buy rating on Allakos (ALLK – Research Report), with a price target of $3.00.Stay Ahead ...
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
Jasper Therapeutics, Inc. (NASDAQ:JSPR) reported preliminary data from the ongoing BEACON Phase 1b/2a study of subcutaneous ...
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile ...
Jasper Therapeutics stock tumbles after study data
Despite the promising clinical data, the over 40% drop in Jasper's stock price indicates that investors may have reservations about the study results or the company's future prospects. As the market ...